Document:

EX-10.1

 Exhibit 10.1 

EXECUTION COPY 
 VOTING
AGREEMENT 
 THIS VOTING AGREEMENT, dated as of May 3, 2015 (this “Agreement”), is entered into by and among the
undersigned stockholders (each, a “Stockholder” and, collectively, the “Stockholders”) of CECO Environmental Corp., a Delaware corporation (“Parent”), and PMFG, Inc., a Delaware corporation (the
“Company”). 
 WHEREAS, as of the date of this Agreement, the Company, Parent, Top Gear Acquisition Inc., a Delaware
corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Top Gear Acquisition II LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (“Successor Sub”), have entered, or
will enter, into an Agreement and Plan of Merger (as the same may be amended from time to time, the “Merger Agreement”), providing for, among other things, (i) the merger of Merger Sub with and into the Company and
(ii) the subsequent merger of the First Step Surviving Corporation with and into Successor Sub (the foregoing clauses (i) and (ii), collectively, the “Mergers”), in each case, pursuant to, and subject to the terms and
conditions of, the Merger Agreement; 
 WHEREAS, as a condition to its willingness to enter into the Merger Agreement, the Company has
required that the Stockholders execute and deliver this Agreement; and 
 WHEREAS, in order to induce the Company to enter into the Merger
Agreement, the Stockholders are willing to make certain representations, warranties, covenants and agreements with respect to the applicable shares of Parent Common Stock beneficially owned by such Stockholders (the “Original
Shares” and, together with any additional shares of Parent Common Stock acquired pursuant to Section 5 hereof, the “Shares”). Any reference herein to “Original Shares” with respect to a particular
Stockholder shall mean the shares of Parent Common Stock set forth below such Stockholder’s signature on the signature page hereto. 

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt, sufficiency and adequacy of which
are hereby acknowledged, the parties hereto agree as follows: 
  

	1.	Definitions. 

 For purposes of this Agreement, capitalized terms used and not defined
herein shall have the respective meanings ascribed to them in the Merger Agreement. For all purposes of and under this Agreement, the following terms shall have the following respective meanings: 

“Constructive Sale” means, with respect to any security, a short sale with respect to such security, entering into or
acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security, or entering into any other hedging or other derivative transaction that has the effect of either
directly or indirectly materially changing the economic benefits or risks of ownership of such security. 
 “Transfer”
means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge, hypothecation, or the grant, creation, or suffrage of a lien, security interest, or encumbrance in or upon, or the gift, grant, or
placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title,
or interest therein, or the record or beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale, or other disposition, and each agreement, arrangement, or understanding, whether or not in writing, to effect any of the
foregoing. 
  

	2.	Representations of Stockholder. 

 Each Stockholder represents and warrants to the Company
that: 
 (a) (i) Such Stockholder owns beneficially (as such term is defined in Rule 13d-3 under the Exchange Act) all of the Original
Shares free and clear of all security interests, liens, claims, pledges, limitations in the 

 
Stockholder’s voting rights, charges or other encumbrances of any nature whatsoever (“Encumbrances”) (except any Encumbrances arising under securities laws or under this
Agreement), and (ii) except pursuant to this Agreement and that certain lockup letter agreement dated the date hereof delivered by such Stockholder to the Company, there are no options, warrants or other rights, agreements, arrangements or
commitments of any character to which such Stockholder is a party relating to the pledge, disposition or voting of any of the Original Shares and there are no voting trusts or voting agreements with respect to the Original Shares, in each case,
which are inconsistent with the terms of this Agreement. 
 (b) Such Stockholder does not beneficially own any shares of Parent Common Stock
other than (i) the Original Shares and (ii) any options, warrants or other rights to acquire any additional shares of Parent Common Stock or any security exercisable for or convertible into shares of Parent Common Stock, set forth on the
signature page of this Agreement (collectively, “Options”). 
 (c) Such Stockholder has full power and authority and legal
capacity to enter into, execute and deliver this Agreement and to perform fully such Stockholder’s obligations hereunder (including the proxy described in Section 3 below). This Agreement has been duly and validly executed and
delivered by such Stockholder and constitutes the legal, valid and binding obligation of such Stockholder, enforceable against such Stockholder in accordance with its terms, subject to the Bankruptcy and Equity Exceptions. 

(d) None of the execution and delivery of this Agreement by such Stockholder, the consummation by such Stockholder of the transactions
contemplated hereby or compliance by such Stockholder with any of the provisions hereof will conflict with or result in a breach, or constitute a default (with or without notice of lapse of time or both) under any provision of, any trust agreement,
loan or credit agreement, note, bond, mortgage, indenture, lease or other agreement, instrument or Law applicable to such Stockholder or to such Stockholder’s property or assets. 

(e) No consent, approval or authorization of, or designation, declaration or filing with, any Governmental Authority or other Person on the
part of such Stockholder is required in connection with the valid execution and delivery of this Agreement, other than the filing of a Schedule 13D/A with the Securities and Exchange Commission. No consent of such Stockholder’s spouse is
necessary under any “community property” or other laws in order for such Stockholder to enter into and perform its obligations under this Agreement. 

(f) Such Stockholder understands and acknowledges that the Company is entering into the Merger Agreement in reliance upon such
Stockholder’s execution and delivery of this Agreement and the representations and warranties and covenants of such Stockholder contained herein. 

(g) The Closing of the Mergers is intended to and will provide material economic benefit to such Stockholder. 

 

	3.	Agreement to Vote Shares; Irrevocable Proxy. 

 (a) Each Stockholder agrees during the
term of this Agreement to vote the Shares, and to cause any holder of record of the Shares to vote or execute a written consent or consents if the stockholders of Parent are requested to vote their shares through the execution of an action by
written consent in lieu of any such annual or special meeting of the stockholders of Parent: (i) in favor of the issuance by Parent of the Parent Common Stock Consideration to be issued in connection with the Closing of the Mergers and any
other action required to consummate the Mergers that may be submitted to a vote of the stockholders of Parent, at every meeting (or in connection with any action by written consent) of the stockholders of Parent at which such matters are considered
and at every adjournment or postponement thereof; (ii) against (1) any action, proposal, transaction or agreement which could reasonably be expected to result in a breach of any covenant, representation or warranty or any other obligation
or agreement of Parent, Merger Sub or Successor Sub under the Merger Agreement or of Stockholder under this Agreement and (2) any action, proposal, transaction or agreement that could reasonably be expected to impede or materially interfere
with, delay, discourage, adversely affect or inhibit the timely consummation of the Mergers or the fulfillment of Parent’s, the Company’s, Merger Sub’s or Successor Sub’s conditions under the

  
 - 2 - 

 
Merger Agreement or change in any manner the voting rights of any class of shares of Parent (including by way of any amendments to Parent’s Certificate of Incorporation or Bylaws). 

Each Stockholder shall retain at all times the right to vote its Shares in its sole discretion and without any other limitation on those
matters other than those set forth in clauses (i) and (ii) that are at any time or from time to time presented for consideration to Parent’s stockholders generally. For the avoidance of doubt, clauses (i) and (ii) shall not
apply to votes, if any, solely on the election or removal of directors as recommended by Parent’s board of directors. 
 (b) Each
Stockholder hereby appoints the Company and any designee of the Company, and each of them individually, its proxies and attorneys-in-fact, with full power of substitution and resubstitution, to vote or act by written consent during the term of this
Agreement with respect to the Shares, but only to the extent provided in and with respect to the matters described in Section 3(a). This proxy and power of attorney is given to secure the performance of the duties of such Stockholder
under this Agreement. Each Stockholder shall take such further action or execute such other instruments as may be reasonably necessary to effectuate the intent of this proxy. This proxy and power of attorney granted by each Stockholder shall be
irrevocable during the term of this Agreement, shall be deemed to be coupled with an interest sufficient in law to support an irrevocable proxy, is intended to be irrevocable during the term of this Agreement in accordance with the provisions of
Section 212 of the Delaware General Corporation Law, and shall revoke any and all prior proxies granted by such Stockholder with respect to the Shares (but only with respect to the matters set forth in Section 3(a)); provided that such
Stockholder may grant subsequent proxies with respect to any matter other than those specified in Section 3(a). The power of attorney granted by each Stockholder herein is a durable power of attorney and shall survive the dissolution,
bankruptcy, death or incapacity of such Stockholder. The proxy and power of attorney granted hereunder shall terminate automatically upon the termination of this Agreement. 

Each Stockholder agrees that such Stockholder will not, and will not permit any entity under such Stockholder’s control to, deposit any
of the Shares in a voting trust, grant any proxies with respect to the Shares or subject any of the Shares to any arrangement with respect to the voting of the Shares, in each case, that would be inconsistent with Section 2 above, other
than agreements entered into with the Company. 
  

	4.	Transfer and Encumbrance. 

 Each Stockholder agrees that during the term of this
Agreement, such Stockholder shall not Transfer any of the Shares or enter into any contract, option or other agreement with respect to, or consent to, a Transfer of, any of the Shares or such Stockholder’s economic interest therein. Any
attempted Transfer of Shares or any interest therein in violation of this Section 4 shall be null and void. 
 Notwithstanding
anything in this Agreement to the contrary, this Agreement will not prohibit any Stockholder from (a) exercising options and/or warrants owned by such Stockholder that are exercisable for shares of Parent Company Stock, it being understood,
acknowledged and agreed that the shares of Parent Common Stock acquired by such Stockholder in connection therewith shall be subject to this Agreement as “Shares”; (b) entering into a plan adopted pursuant to Rule 10b5-1 under the
Securities Exchange Act of 1934, as amended, to the extent that such plan does not allow for any Transfer of Shares during the term of this Agreement; or (c) making (i) bona fide gifts of such Stockholder’s Shares to family members or
family trusts, (ii) any transfer by will or intestacy in case of death or (iii) any Transfer of such Stockholder’s Shares for estate planning purposes to persons immediately related to such transferor by blood, marriage or adoption,
or any trust solely for the benefit of such transferor and/or the persons described in the preceding clause, provided, however, that with respect to each of the Transfers described in clause (c) of this sentence, prior, and as a condition
precedent, to such transfer, the transferee, or the trustee or legal guardian on behalf of any transferee, agrees in writing to be bound by the terms of this Agreement. For purposes hereof, “immediate family” shall mean any relationship by
blood, marriage or adoption, not more remote than first cousin (including, without limitation, lineal descendants, stepchildren, father, mother, brother, sister of the applicable Stockholder or the applicable Stockholder’s spouse). In addition
to the foregoing, in the event a Stockholder is an entity rather than an 

  
 - 3 - 

 
individual, this Agreement will not prevent any transfer of any or all of such Stockholder’s Shares to the stockholders of such entity, if it is a corporation, to the members of such entity,
if it is a limited liability company, or to the partners of such entity, if it is a partnership; provided, however, that in each such case, it shall be a condition to the transfer that such transferee agrees in writing prior to such transfer to be
bound by the terms of this Agreement. 
  

	5.	Additional Shares. 

 Each Stockholder agrees that all shares of Parent Common Stock that
such Stockholder purchases, acquires the right to vote or otherwise acquires beneficial ownership (as defined in Rule 13d-3 under the Exchange Act) of after the execution of, and prior to the termination of, this Agreement shall be subject to the
terms of this Agreement and shall constitute Shares for all purposes of this Agreement. 
  

	6.	Termination. 

 This Agreement shall terminate upon the earliest to occur of (a) the
First Step Effective Time, (b) the date on which the Merger Agreement is terminated in accordance with its terms, and (c) the mutual agreement of the Company and the Stockholders to terminate this Agreement; provided, however, that
(i) Section 11 shall survive the termination of this Agreement, and (ii) the termination of this Agreement shall not relieve the Stockholders from any liability for any inaccuracy in or breach of any representation, warranty, or
covenant contained in this Agreement. 
  

	7.	No Agreement as Director or Officer. 

 Each Stockholder makes no agreement or
understanding in this Agreement in such Stockholder’s capacity as a director or officer of Parent or any of its subsidiaries (if such Stockholder holds any such directorship or office), and nothing in this Agreement: (a) will limit or
affect any actions or omissions taken by such Stockholder in such Stockholder’s capacity as such a director or officer, including in exercising rights under the Merger Agreement, and no such actions or omissions shall be deemed a breach of this
Agreement or (b) will be construed to prohibit, limit or restrict such Stockholder from exercising such Stockholder’s fiduciary duties as an officer or director of Parent or its stockholders. 

 

	8.	Specific Performance. 

 Each party hereto acknowledges that it may be difficult to
measure in money the damage to the other party if a party hereto fails to comply with any of the obligations imposed by this Agreement and that, in the event of any such failure, the other party may not have an adequate remedy at law or damages.
Accordingly, each party hereto agrees that each other party may seek injunctive relief or other equitable remedies, in addition to remedies at law or damages, for any such failure. Each party hereto agrees that it will not seek, and agrees to waive
any requirement for, the securing or posting of a bond in connection with the other party’s seeking or obtaining such equitable relief. 
  

	9.	Entire Agreement. 

 This Agreement supersedes all prior agreements, written or oral,
between the parties hereto with respect to the subject matter hereof and contains the entire agreement between and among the parties with respect to the subject matter hereof. This Agreement may not be amended or supplemented, and no provisions
hereof may be modified or waived, except by an instrument in writing signed by each of the parties hereto. No waiver of any provisions hereof by any party shall be deemed a waiver of any other provisions hereof by such party, nor shall any such
waiver be deemed a continuing waiver of any provision hereof by such party. 
  

	10.	Notices. 

 All notices, consents, requests, claims and demands under this Agreement shall
be in writing and shall be deemed given in accordance with the Merger Agreement: (i) if to the Company, to the address, e-mail address, or 

  
 - 4 - 

 
facsimile provided in the Merger Agreement, including to the Persons designated therein to receive copies; and (ii) if to a Stockholder, to such Stockholder’s address, e-mail address,
or facsimile shown below such Stockholder’s signature on the signature page hereto. 
  

	11.	Miscellaneous. 

 (a) This Agreement shall be governed by and construed in accordance with
the Laws of the State of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of law thereof. 

(b) For all actions, suits and proceedings arising out of or relating to this Agreement, the parties hereby irrevocably and unconditionally
(a) consent to the personal jurisdiction of any state or federal court of competent jurisdiction located in the City of Wilmington in the State of Delaware and (b) waive any defense or objection to proceeding in such court, including those
objections and defenses based on an alleged lack of personal jurisdiction, improper venue and forum non-conveniens. The parties acknowledge that all directions issued by any such court, including all injunctions and other decrees, will be binding
and enforceable in all jurisdictions and countries. Process in any such suit, action or proceeding may be served on any party anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each
party agrees that service of process on such party as provided in Section 10 shall be deemed effective service of process on such party. 

(c) The Company may seek to enforce the terms and conditions of this Agreement against one or more Stockholders, and any breach of this
Agreement by a Stockholder shall not relieve the non-breaching Stockholders from the obligations imposed on such Stockholders hereunder. 

(d) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND
DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS
AGREEMENT. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A
LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS SECTION 11(d). 
 (e) If any term or provision of this Agreement is invalid, illegal or unenforceable in any
jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any
term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in
order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible. 
 (f) This
Agreement may be executed in one or more counterparts, and by the different Parties in separate counterparts, each of which when executed shall be deemed to be an original, but all of which shall constitute one and the same agreement. 

(g) Each party hereto shall execute and deliver such additional documents as may be necessary or desirable to effect the transactions
contemplated by this Agreement. 

  
 - 5 - 

 (h) The words “hereof,” “herein” and “hereunder” and words of
similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and Section references are to this Agreement unless otherwise specified. Whenever the words
“include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” Unless the context otherwise requires, “or” is not exclusive.
The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms and to the masculine as well as to the feminine and neuter genders of such term. This Agreement shall be construed without regard to
any presumption or interpretation against the party drafting or causing any instrument to be drafted. 
 (i) The obligations of each
Stockholder set forth in this Agreement shall not be effective or binding upon Stockholder until after such time as the Merger Agreement is executed and delivered by the Company, Parent, Merger Sub and Successor Sub. 

(j) This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of the parties and their respective
successors and permitted assigns, including the Stockholders’ estates and heirs upon the death of any of the Stockholders, provided that except as otherwise specifically provided herein, neither this Agreement nor any of the rights, interests,
or obligations of the parties may be assigned or delegated by any of the parties without prior written consent of the other parties. Any assignment in violation of the foregoing shall be void and of no effect. Nothing in this Agreement is intended
to confer on any Person (other than the parties hereto and their respective successors and assigns) any rights or remedies of any nature. 

(k) The obligations of Stockholder set forth in this Agreement shall not be effective or binding upon Stockholder until after such time as the
Merger Agreement is executed and delivered by the Company, Parent, Merger Sub and Successor Sub. 
 [Remainder of Page Intentionally Left
Blank; Signature Page Follows] 

  
 - 6 - 

 IN WITNESS WHEREOF, the parties hereto have executed and delivered this Agreement as of the date
first written above. 
  

			
	PMFG, INC.		

			
		
	By:		 /s/ Peter J. Burlage

			
		
	Name:		 Peter J. Burlage

	Title:		 Chairman and Chief Executive Officer

 Signature Page to Voting Agreement 

					
	JASON DEZWIREK		ICARUS INVESTMENT CORP.
			
	 /s/ Jason DeZwirek
		By:		 /s/ Jason DeZwirek

			Name: /s/ Jason DeZwirek
		
	Number of Shares of Parent Common Stock Beneficially Owned as of the Date of this Agreement: 1,361,770*		Number of Shares of Parent Common Stock Beneficially Owned as of the Date of this Agreement: 2,574,736
	  
 Number of Warrants/Options Beneficially Owned as of the Date of this
Agreement: 0*
		  
 Number of Warrants/Options Beneficially Owned as of the
Date of this Agreement: 250,000

	  
 Address: 2300 Yonge Street
		  
 Address: 2300 Yonge Street

	 Suite 1710
		 Suite 1710

	 Toronto, Ontario, Canada
		 Toronto, Ontario, Canada

	 MP 1E4
		 MP 1E4

	Fax: (416) 480-2803		Fax: (416) 480-2803
	E-mail: Jason@dezwirek.com		E-mail: Jason@dezwirek.com
	  
 *  Excludes shares
of Parent Common Stock and Warrants/Options owned directly by Icarus Investment Corp.
		

 Signature Page to Voting Agreementexas_Ex10-1

		
			CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR SUCH PORTIONS. ASTERISKS DENOTE OMISSIONS.
		

		
			Exhibit 10.1
		

		
			MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
		

		
			AMENDED AND RESTATED LICENSE AGREEMENT
		

		
			 
		

		
			This Amended and Restated License Agreement is by and between MAYO Foundation for Medical Education and Research, a Minnesota charitable corporation, located at 200 First Street SW, Rochester, Minnesota 55905-0001 (“MAYO”), and Exact Sciences Corporation, a for-profit company located at 441 Charmany Drive, Madison, WI 53719 (“EXACT”), each a “Party”, and collectively, “Parties”.
		

		
			 
		

		
			WHEREAS, EXACT and MAYO entered into that certain License Agreement effective 12 June 2009 together with the following amendments:
		

		
			1.Amendment No. 1 effective as of 1 January 2010;
		

		
			2.Amendment No. 2 effective as of 17 February 2011;
		

		
			3.Amendment No. 3 effective as of 26 March 2010; and
		

		
			4.Amendment No. 4 effective as of May 15, 2012; and
		

		
			5.Letter Agreement effective as of April 1, 2014;
		

		
			collectively referred to as the “Original Agreement”).
		

		
			 
		

		
			WHEREAS, EXACT and MAYO  are desirous of amending and restating the Original Agreement in its entirety and creating a single amended and restated agreement on the terms set forth below ("Restated Agreement");
		

		
			 
		

		
			WHEREAS, MAYO desires to make its intellectual property rights available for the development and commercialization of products, methods and processes for public use and benefit;
		

		
			 
		

		
			WHEREAS, EXACT represents itself as being knowledgeable in developing and commercializing tests for the detection of Gastrointestinal cancer; and
		

		
			 
		

		
			WHEREAS, MAYO is willing to grant and EXACT is willing to accept an exclusive license under such rights for the purpose of developing such diagnostic tests;
		

		
			 
		

		
			NOW THEREFORE, in consideration of the foregoing and the terms and conditions set forth below, the Parties hereby agree as follows:
		

		
			 
		

		
			Article 1.00 — Definitions
		

		
			 
		

		
			For purposes of this Restated Agreement, the terms defined in this Article will have the meaning specified and will be applicable both to the singular and plural forms:
		

		
			 
		

		
			1.01For MAYO, “Affiliate”: any corporation or other entity within the same “controlled group of corporations” as MAYO or its parent Mayo Clinic.  For purposes of this definition, the term “controlled group of corporations” will have the same definition as Section 1563 of the Internal Revenue Code as of 10 November 1998, but will include corporations or other entities which, if not a stock corporation, more than 50% of the board of directors or other governing
		

		
			 
		

		

		

		 

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 2 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		body of such corporation or other entity is controlled by a corporation within the controlled group of corporations of MAYO or Mayo Clinic.  MAYO’s Affiliates include, but are not limited to: Mayo Clinic; Mayo Collaborative Services, LLC; Mayo Clinic Hospital–Rochester;   Mayo Clinic Rochester; Mayo Clinic Florida; Mayo Clinic Arizona; and its Mayo Health System entities.  MAYO will provide EXACT with a list of current Affiliates by January 31 of each calendar year.    
		

		
			 
		

		
			For EXACT, “Affiliate”: any corporation or other entity that controls, is controlled by, or is under common control with, EXACT.  For purposes of this definition, “control” means ownership of: (a) at least 50% of the outstanding voting securities of such entity; or (b) at least 50% of the decision-making authority of such entity.
		

		
			 
		

		
			1.02“Change of Control”: a merger, acquisition, consolidation or other transaction or series or related transactions following which the holders of EXACT’s outstanding voting securities prior to such transaction hold less than 50% of the outstanding voting securities of the acquiring or surviving corporation or a sale, license or transfer of all or substantially all of EXACT’s assets to which this Restated Agreement relates to a third party that is not an Affiliate of EXACT. 
		

		
			 
		

		
			1.03“Cologuard”:  non-invasive colon cancer screening test developed by EXACT and approved by the U.S. Food and Drug Administration on August 19, 2014, including any Update, Improvement or Replacement of Cologuard.
		

		
			 
		

		
			1.04“Confidential Information”: any information or material disclosed by one Party, the disclosing party, to the other, the receiving party, identified in writing as confidential at the time of disclosure or, if first disclosed orally, identified as confidential and confirmed in writing within forty-five days.  Confidential Information expressly includes Know How and data and inventions generated in connection with the Sponsored Research Agreement, activities pursuant to Section 2.06 hereto, and employing materials or data transferred from EXACT to MAYO.  Confidential Information does not include any information or material that the receiving party evidences is: (a) already known to the receiving party at the time of disclosure (other than from the disclosing party); (b) publicly known other than through acts or omissions of the receiving party; (c) disclosed to the receiving party by a third party who was not and is not under any obligation of confidentiality; or (d) independently developed by employees of the receiving party without knowledge of or access to the Confidential Information.
		

		
			 
		

		
			1.05“Effective Date”: January 31, 2015.
		

		
			 
		

		
			1.06“Gastrointestinal”:  any organ that exfoliates cells into the lumen of the gastrointestinal tract (i.e. (a) primary GI organs:  esophagus, stomach, pancreas, small intestine, liver, bile duct, colon and rectum; (b) airway:  pharynx, larynx, trachea, bronchi and lungs; and (c) head and neck:  nasal passages, mouth and throat).
		

		
			 
		

		
			1.07“FDA”:  the United States Food and Drug Administration or any successor agency.
		

		
			 
		

		

		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 3 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		1.08“Field”:  any screening, surveillance or diagnostic test or tool intended for use in connection with any Gastrointestinal cancer, Gastrointestinal precancer, Gastrointestinal disease or Gastrointestinal condition. 
		

		
			 
		

		
			1.09“Know-How”:
		

		
			 
		

		
			(a)research and development information, materials, technical data, unpatented inventions, know-how and supportive information of Dr. Ahlquist and his laboratory as of the Original Agreement Effective Date and also as of the Effective Date of this Restated Agreement to the extent it is necessary for the development or manufacture of a Licensed Product.  As of the Effective Date of the Restated Agreement, such Know-How includes MAYO File numbers:
		

			
	
			
				i.
			

			
	
			
			2009-128 - “Method to Enrich Genomic DNA in Stool”; 

			
	
			
				ii.
			

			
	
			
			2009-130 - “In Vivo Approaches to Improve Fecal Recovery of Nucleic Acids Exfoliated for Aerodigestive Neoplasms”;

			
	
			
				iii.
			

			
	
			
			2013-179 – “Novel Methylated Markers for the Detection of Stomach Cancer”;

			
	
			
				iv.
			

			
	
			
			2014-068 - “Universal Neoplasm Detection and Site-Prediction by Assay of Highly Discriminant Methylated DNA Markers in Buffy Coat”; 

			
	
			
				v.
			

			
	
			
			2014-069 - “Novel Methylated DNA Markers for Detection of Colorectal Neoplasia from Common Buffy Coat Samples”; 

			
	
			
				vi.
			

			
	
			
			2014-372 – “Novel Methylated DNA Markers for the Detection of Adenocarcinoma and Squamous Carcinoma of the Esophagus”;

			
	
			
				vii.
			

			
	
			
			2015-040 – “Methylated DNA Markers for the Detection of Barrett’s Esophagus (BE) and Barrett’s Esophagus with Dysplasia (BED)”;

			
	
			
				viii.
			

			
	
			
			2015-041 – “Combining Stool-Based Non-Coding Small RNA and DNA Biomarkers for the Detection of Pancreatic Cancer”;

			
	
			
				ix.
			

			
	
			
			2015-042 – “DNA Methylation Markers for Universal and Site Prediction of Human Neoplasia”; and

			
	
			
				x.
			

			
	
			
			2015-043 – “Cell-Specific Methylation Markers to Enhance Disease Detection”.

		
			 
		

		
			(b)research and development information, technical data, unpatented inventions, know-how and supportive information developed by Dr. Ahlquist and/or other individuals as a result of Dr. Ahlquist’s activities pursuant to Section 2.06 to the extent it is necessary for the development or manufacture of a Licensed Product; and
		

		
			 
		

		
			(c)research and development information, technical data, unpatented inventions, know-how and supportive information developed by MAYO as a result of MAYO’s activities under the Sponsored Research Agreement to the extent it is necessary for the development or manufacture of a Licensed Product.
		

		
			 
		

		
			1.10“Lung Cancer Collaboration Licensed Product”:  any Licensed Product relating to 
		

		
			screening for, or the diagnosis of, lung cancer or precancer that is developed in whole or in part pursuant to a collaboration between EXACT and a third party.  
		

		
			 
		

		
			1.11“Licensed Product”: any product or process: (a) described by a pending claim of the Patent Rights; (b) infringing an issued claim of the Patent Rights, or that would infringe but for the exception in 35 U.S.C. §271(e)(1), or similar exception in the United States or other 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 4 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		countries; (c) the development, manufacture, use, sale, offer for sale or importation of which incorporates, uses, was derived from, identified by, validated, or developed in whole or in part using the Know-How; and/or (d) the manufacture, use, sale, offer for sale or importation of which incorporates, uses, or was derived from MAYO Materials.
		

		
			 
		

		
			1.12“Materials”:  
		

		
			 
		

		
			(a)MAYO Materials are biological specimens of human origin, including without limitation tissues, blood, plasma, urine, stool and derivatives thereof used by MAYO pursuant to work in Dr. Ahlquist’s laboratory within the Field pursuant to Section 2.06 hereto or provided by MAYO (including without limitation by Dr. Ahlquist) to EXACT for use within the Field.
		

		
			 
		

		
			(b)EXACT Materials include any material provided to MAYO pursuant to Section 2.06 hereto. 
		

		
			 
		

		
			1.13“Net Sales”: the amount invoiced by EXACT or Sublicensee for the transfer of a Licensed Product to a third party less documented: (a) sales, excise or use taxes shown on the face of the invoice, excluding value-added tax; (b) credits for defective or returned Licensed Products actually given; and (c) regular trade and discount allowances given.  Leasing, lending, consigning or any other activity by means of which a third party acquires the right to possess or use a Licensed Product is a transfer for the purpose of determining Net Sales.  Net Sales on Licensed Products transferred as part of a non-cash exchange or other than to third parties shall be calculated at the then-current customary sales price invoiced to third parties or fair market value if there are no current invoices to third parties.  Net Sales accrues with the first of delivery or invoice.
		

		
			 
		

		
			1.14“Original Agreement Effective Date”:  June 12, 2009
		

		
			 
		

		
			1.15“Patent Rights”:
		

		
			 
		

		
			(a)U.S. patents and applications listed in Exhibit A hereto, together with divisionals, continuations, and continuations-in-part (but only for subject matter supported pursuant to 35 U.S.C. §112 by the foregoing) therefrom, patents issuing thereon, re-examinations and re-issues thereof, as well as extensions and supplementary protection certificates and any foreign counterpart of any of the foregoing;
		

		
			 
		

		
			(b)Any patent applications filed as a result of Dr. Ahlquist’s, or any other, Gastrointestinal-related activities pursuant to Section 2.06 hereto, together with divisionals, continuations, and continuations-in-part (but only for subject matter supported pursuant to 35 U.S.C. §112 by the foregoing) therefrom, patents issuing thereon, re-examinations and re-issues thereof, as well as extensions and supplementary protection certificates and any foreign counterpart of any of the foregoing;
		

		
			 
		

		
			(c)Any patent applications filed with MAYO inventors as a result of activities performed by MAYO under the work plans that are part of the Sponsored Research Agreement, together with divisionals, continuations, and continuations-in-part (but only for subject matter 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 5 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		supported pursuant to 35 U.S.C. §112 by the foregoing) therefrom, patents issuing thereon, re-examinations and re-issues thereof, as well as extensions and supplementary protection certificates and any foreign counterpart of any of the foregoing; and
		

		
			 
		

		
			(d)Any patent applications filed disclosing or describing data generated using EXACT materials or reagents provided by EXACT to MAYO
		

		
			 
		

		
			Exhibit A shall be updated on a semi-annual basis.  A patent or patent application shall be added, or deemed added, to Exhibit A if either: i) it is a patent or patent application defined by any of 1.15(b), (c) or (d); or ii) MAYO provides written confirmation that the patent or patent application is within Patent Rights.
		

		
			 
		

		
			1.16 “PMA”:  FDA Premarket Approval Application.
		

		
			 
		

		
			1.17“Sponsored Research Agreement”: the agreement outlining the research to be funded by EXACT and performed at MAYO, as agreed upon by the Parties in accordance with the Original  Agreement.  The Sponsored Research Agreement is also the mechanism whereby MAYO bills EXACT on a monthly or quarterly basis, as needed, for support of research expenses for mutually agreed upon protocols/budgets for EXACT-MAYO collaborations.  
		

		
			 
		

		
			1.18“Sublicensee”: any third party or any Affiliate to whom EXACT has conveyed rights or the forbearance of suit under the Patent Rights, Know-How & Materials.
		

		
			 
		

		
			1.19“Term”: begins on the Original Agreement Effective Date and ends, subject to Article 10, upon the date of the last to expire of the Patent Rights, unless the Know-How or Materials are still in use in a manner generating Net Sales, in which case upon the earlier of five (5) years following the last to expire of the Patent Rights or the date upon which EXACT ceases such use of the Know-How or Materials.
		

		
			 
		

		
			1.20“Territory”: worldwide.
		

		
			 
		

		
			1.21“Update, Improvement or Replacement”:  an assay that modifies an existing FDA-approved assay and is FDA compliant without the requirement of a de novo PMA.
		

		
			 
		

		
			Article 2.00 — Grant of Rights
		

		
			 
		

		
			2.01GRANT.  Subject to the terms and conditions of this Restated Agreement, MAYO grants to EXACT: (a) an exclusive license with the right to sublicense, within the Field and Territory, under the Patent Rights to make, have made, use, offer for sale, sell, and import Licensed Products; and (b) a nonexclusive license with the right to sublicense, within the Field and Territory, to use the Know-How to develop, make, have made, use, offer for sale, sell, and import Licensed Products.
		

		
			 
		

		
			2.02RESERVATION OF RIGHTS.  All rights herein are subject to (a) the rights and obligations to and requirements of the U.S. government, if any have arisen or may arise, regarding the Patent Rights, including as set forth in 35 U.S.C. §§200 et al., 37 C.F.R. Part 401 et 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 6 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		al. (“Bayh-Dole Act”); and (b) MAYO’s and its Affiliates’ reserved, irrevocable right to practice and have practiced the Patent Rights in connection with MAYO’s and its Affiliates’ educational,  research and non-commercial, and non-competitive with EXACT, clinical programs (for the avoidance of doubt, MAYO  will not practice the Patent Rights to develop or offer to third parties products or services that are competitive to any product or service offered or sold by EXACT or its Affiliates).  EXACT agrees to comply with the provisions of the Bayh-Dole Act, to the extent such act applies, including promptly providing to MAYO with information requested to enable MAYO to meet its compliance requirements and substantially manufacturing Licensed Product in the U.S.
		

		
			 
		

		
			2.03NO OTHER RIGHTS GRANTED.  This Restated Agreement does not grant any right, title or interest in or to any tangible or intangible property right of MAYO or its Affiliates, including any improvements thereon, or to any Patent Rights or Know-How & Materials outside the Field or Territory that is not expressly stated in Section 2.01 or 2.07.  All such rights, titles and interests are expressly reserved by MAYO and EXACT agrees that in no event will this Restated Agreement be construed as a sale, an assignment, or an implied license by MAYO or its Affiliates to EXACT of any such tangible or intangible property rights.  This Restated Agreement does not grant any right, title or interest in or to any tangible or intangible property right of EXACT or its Affiliates, including rights in jointly owned intellectual property, unless expressly recited herein.
		

		
			 
		

		
			2.04SUBLICENSES.  Any sublicense by EXACT shall be to a Sublicensee that agrees in writing to be bound by substantially the same terms and conditions as EXACT herein, and with the financial terms and conditions at least as favorable to MAYO as set forth in the Restated Agreement, or such sublicense shall be null and void.  Sublicenses granted hereunder shall not be transferable, including by further sublicensing, delegatable or assignable without the prior written approval of MAYO.  EXACT will provide MAYO with a copy of each sublicense agreement promptly after execution.  EXACT is responsible for the performance of all Sublicensees as if such performance were carried out by EXACT itself, including the payment of any royalties or other payments provided for hereunder triggered by Sublicensee, regardless of whether the terms of any sublicense require that Sublicensee pay such amounts (such as in a fully paid-up license), or that such amounts be paid by the Sublicensee directly to MAYO.  Each sublicense agreement shall name MAYO as a third party beneficiary and unless MAYO has provided written consent, all rights of Sublicensees shall terminate when EXACT’s rights terminate.
		

		
			 
		

		
			2.05USE OF MATERIALS.
		

		
			 
		

		
			(a)MAYO Materials.
		

		
			 
		

		
			i.Use of the MAYO Materials by MAYO or EXACT shall be subject to the prior approvals of MAYO’s Institutional Review Board and the Mayo Clinic Research Biospecimen Subcommittee.
		

		
			 
		

		
			ii.MAYO Materials are owned by MAYO and any transfer of such MAYO Materials to EXACT under the terms of this Restated Agreement shall not affect MAYO’s 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 7 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		ownership interest therein.  MAYO shall clearly mark and identify all MAYO Materials transferred to EXACT.  All MAYO Materials will be maintained by EXACT so that such MAYO Materials are readily identifiable.  The transfer of MAYO Materials to EXACT gives EXACT no rights in such MAYO Materials other than those specifically set forth in this Restated Agreement.  EXACT agrees to use the MAYO Materials solely for research purposes and shall not transfer, deliver or otherwise release such Materials to a third party without the express prior written consent of MAYO.  Upon expiration of a project and at the instructions of MAYO, EXACT shall either return to MAYO or destroy all unused MAYO Materials.
		

		
			 
		

		
			iii.EXACT agrees to use the MAYO Materials in accordance with the rights granted to EXACT under this Restated Agreement.  All research conducted by EXACT using the MAYO Materials shall be conducted in accordance with all applicable state and federal laws regarding such research.
		

		
			 
		

		
			iv.Nothing in this Restated Agreement provides EXACT the right to transfer nucleic acids or any other material extracted from MAYO Materials to any third-party.
		

		
			 
		

		
			(b)EXACT Materials.
		

		
			 
		

		
			i.MAYO agrees to use the EXACT Materials solely for purposes pursuant to Section 2.06 hereto.  Upon expiration of a project and at the instructions of EXACT, MAYO shall either return to EXACT or destroy all unused EXACT Materials.
		

		
			 
		

		
			ii.All research conducted by MAYO using the EXACT Materials shall be conducted in accordance with all applicable state and federal laws regarding such research.
		

		
			 
		

		
			iii.MAYO shall not transfer, deliver or otherwise release EXACT Materials to a third party without the express prior written consent of EXACT.
		

		
			iv.MAYO shall treat the EXACT Materials and related information as Confidential Information under Article 8 hereto. 
		

		
			 
		

		
			2.06MAYO AND AHLQUIST COMMITMENT TO CONFER.
		

		
			 
		

		
			(a)MAYO will collaborate with EXACT on the development of Licensed Products, including sharing Know-How and providing access to MAYO Materials and laboratory equipment, conducting scientific studies, providing biostatistical support, and making submissions for peer-reviewed publications (MAYO file #2009-169; Know-How Related to Development, with Exact Sciences, of a Product for the Screening of Patients for Colorectal and other Aerodigestive Cancers Using Stool Samples”).
		

		
			 
		

		
			(b)For five (5) years after the Effective Date, subject of MAYO approval, and for so long as Dr. Ahlquist is an employee of MAYO, Dr. Ahlquist will consult on, collaborate with, and oversee EXACT on product development efforts, as a special advisor to the EXACT board of directors and senior management.  EXACT will confer with Dr. Ahlquist in person in Rochester, MN, Madison, WI or as mutually agreed, or by telephone.  All travel expenses 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 8 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		incurred by Dr. Ahlquist in this role as advisor shall be paid by EXACT.  EXACT anticipates Dr. Ahlquist will contribute up to 100% of his time to services for EXACT.  MAYO shall be solely responsible for compensating Dr. Ahlquist, provided, however, that in consideration of the services provided under this Section 2.06(b), EXACT shall pay MAYO the amounts set forth in Section 3.05.  If for any reason Dr. Ahlquist becomes unavailable to direct the performance of the work under this Restated Agreement, MAYO shall notify Exact and the Parties will work together to identify a mutually acceptable successor to provide the advisory services formerly provided by Dr. Ahlquist, as well as mutually acceptable compensation to replace that described in Section 3.05 for Dr. Ahlquist, with the intent to keep Dr. Ahlquist’s research team and projects intact; provided, however, if the Parties fail to agree on a mutually acceptable successor within a reasonable period of time, Exact may, upon written notice to MAYO, terminate the Parties’ obligations under this Section 2.06(b) as well as EXACT’s payment obligations under Section 3.05 (for the avoidance of doubt, any such terminations shall not have the effect of terminating EXACT’s other rights under this Restated Agreement, including without limitation its license rights).  
		

		
			 
		

		
			(c)Notwithstanding EXACT’s rights to sublicense pursuant to Section 2.01 hereto, EXACT shall not have the right to sublicense any obligation of Dr. Ahlquist to confer.  In addition, in the event of a Change of Control, MAYO may, within thirty (30) days of the effective date of such Change of Control, terminate the Parties’ obligations under Section 2.06(b), which shall automatically result in the termination of EXACT’s payment obligations under Section 3.05 (for the avoidance of doubt, any such terminations shall not have the effect of terminating EXACT’s other rights under this Restated Agreement, including without limitation its license rights).
		

		
			 
		

		
			2.07LICENSE GRANT FOR NEW MARKERS.  MAYO grants to EXACT a perpetual exclusive license with the right to sublicense, to make, have made, use, offer for sale, sell, and import Licensed Products that incorporate, use, or derive from any markers identified by MAYO during the period specified as “MAYO and Ahlquist Commitment to Confer” in Section 2.06 hereto, whether such markers are patented or unpatented.  MAYO represents and warrants that all such markers that have been identified as of the Effective Date are listed on Exhibit B hereto, and MAYO agrees that it shall update Exhibit B from time to time to include all new markers within the Field.  Exhibit B shall be updated on a semi-annual basis.  All rights granted under this Section 2.07 are subject to MAYO’s and its Affiliates’ reserved, irrevocable right to use such markers in connection with MAYO’s and its Affiliates’ educational, research and non-commercial, and non-competitive with EXACT, clinical programs (for the avoidance of doubt, MAYO will not use such markers to develop or offer to third parties products or services that are competitive to any product or service offered or sold by EXACT or its Affiliates). 
		

		
			 
		

		
			Article 3.00 —Consideration and Royalties
		

		
			 
		

		
			3.01INITIAL CONSIDERATION AND OTHER PAYMENTS TO MAYO
		

		
			 
		

		
			(a)The Parties acknowledge that on July 9, 2009, following execution of the Original Agreement, EXACT paid MAYO an up-front payment of EIGHTY THOUSAND DOLLARS (US $80,000) as consideration for entering into the Original Agreement. This initial payment is 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 9 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		nonrefundable and is not an advance or creditable against any royalties otherwise due under this Restated Agreement.
		

		
			 
		

		
			(b)The Parties acknowledge that on June 10, 2009, following execution of the Original Agreement, EXACT issued to MAYO the following nonrefundable and noncreditable warrants:
		

		
			 
		

		
			(i)1,000,000 warrants (as consideration for the licenses granted under the Original Agreement) under the terms and conditions of the warrant agreement attached to the Original Agreement as Exhibit C; and
		

		
			 
		

		
			(ii)250,000 warrants (as partial consideration for the Know-How services provided pursuant to Section 2.06) with a four-year vesting schedule under the terms and conditions of the warrant agreement attached to the Original Agreement as Exhibit D.
		

		
			 
		

		
			The strike price of the warrants was based on an average of the daily closing price of EXACT shares for the two weeks prior to the Original Agreement Effective Date.  The warrant agreements included a cashless exercise provision and a six year term extending from the date of issuance of the warrant or, in the case of warrants subject to vesting, the date the warrants vest.
		

		
			 
		

		
			(c)The Parties acknowledge that on July 21, 2011, EXACT paid a nonrefundable and noncreditable milestone fee to MAYO of TWO HUNDRED FIFTY THOUSAND DOLLARS (US $250,000) for commencement of patient enrollment in the human cancer screening clinical trial, in support of a PMA for Cologuard.
		

		
			 
		

		
			(d)The Parties acknowledge that on September 8, 2014, EXACT paid a nonrefundable and noncreditable milestone fee to MAYO of FIVE HUNDRED THOUSAND DOLLARS (US $500,000) upon FDA approval of Cologuard.
		

		
			 
		

		
			(e)The Parties acknowledge that EXACT has provided MAYO with the following additional consideration in connection with the Original Agreement:  ONE MILLION DOLLARS (US $1,000,000) in restricted stock (97,460 shares) was granted on 15 May 2012 (Mayo file 2012-130).  Such restricted stock vests over four (4) years from 15 May 2012 (with one quarter (1⁄4) vested on 15 May 2012, one quarter (1⁄4) vested on 15 May 2013; one quarter (1⁄4) vested on 15 May 2014 and one quarter (1⁄4) to vest on 15 May 2015), subject to MAYO’s continued compliance with its obligations under the Restated Agreement).  .
		

		
			 
		

		
			(f)The Parties acknowledge that EXACT paid MAYO minimum, annual, nonrefundable, noncreditable royalties of (i) TEN THOUSAND DOLLARS (US $10,000) on June 12, 2012;  (ii) TWENTY-FIVE THOUSAND DOLLARS (US $25,000) on September 18, 2013; and (iii) TWENTY-FIVE THOUSAND DOLLARS (US $25,000) on June 26, 2014. 
		

		
			 
		

		
			(g)ADDITIONAL CONSIDERATION.   As additional consideration for the services provided under Section 2.06(b) of this Restated Agreement, EXACT shall make five (5) annual payments to MAYO of ONE MILLION DOLLARS ($1,000,000) each, commencing on February 10, 2015 (with the second such payment due on January 31, 2016, the third such 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 10 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		payment due on January 31, 2017, the fourth annual payment due on January 31, 2018 and the fifth annual payment due on January 31, 2019); provided, however, that EXACT’s obligation to make the payments set forth in this Section 3.01(g) shall terminate upon EXACT’s termination of the Parties’ obligations under Section 2.06(b) pursuant to its termination rights under Section 2.06(b); and provided further, however, that the payments set forth in this Section 3.01(g) shall accelerate and become due and payable in full within thirty (30) days following the effective date of MAYO’s termination of the Parties’ obligations under Section 2.06(b) pursuant to its termination rights under Section 2.06(c) resulting from a Change of Control.  Within MAYO, this additional consideration shall be equally divided among MAYO files 2010-325, 2014-068, 2014-069, 2015-040, 2015-041, 2015-042 and 2015-043.  
		

		
			 
		

		
			3.02MILESTONE FEES.  EXACT will pay the following nonrefundable and noncreditable milestone fees to MAYO:  
		

		
			 
		

		
			(a)TWO HUNDRED THOUSAND DOLLARS (US $200,000) cash payment, paid in two annual installments of ONE HUNDRED THOUSAND DOLLARS ($100,000) each, over a two (2) year period, upon each Licensed Product (other than a Lung Cancer Collaboration Licensed Product) launched after the Effective Date reaching FIVE MILLION DOLLARS (US $5,000,000) in cumulative Net Sales;  
		

		
			 
		

		
			(b)SEVEN HUNDRED FIFTY THOUSAND DOLLARS (US $750,000) cash payment, paid in two annual installments of THREE HUNDRED SEVENTY-FIVE THOUSAND DOLLARS ($375,000) each, over a two (2) year period, upon each Licensed Product (other than a Lung Cancer Collaboration Licensed Product) launched after the Effective Date reaching TWENTY MILLION DOLLARS (US $20,000,000) in cumulative Net Sales;
		

		
			 
		

		
			(c)TWO MILLION DOLLARS (US $2,000,000) cash payment, paid in two annual installments of ONE MILLION DOLLARS ($1,000,000) each, over a two (2) year period, upon each Licensed Product (other than a Lung Cancer Collaboration Licensed Product) launched after the Effective Date reaching FIFTY MILLION DOLLARS (US $50,000,000) in cumulative Net Sales.
		

		
			 
		

		
			(d)For the avoidance of doubt, the Parties acknowledge and agree that Cologuard was launched prior to the Effective Date.
		

		
			 
		

		
			3.03EARNED ROYALTIES.  EXACT will make nonrefundable and noncreditable earned royalty payments to MAYO of a percentage of Net Sales of Licensed Products (“Earned Royalties”).  The Earned Royalties are payable as described in Section 4.01.  Licensed Products transferred to MAYO or its Affiliates are not considered transfers for purposes of determining Net Sales or for calculating Earned Royalties.  No Earned Royalties are due MAYO on transfers to MAYO or MAYO Affiliates.  In addition, no Earned Royalties are due MAYO with respect to Licensed Products, or transfers of Licensed Products, that are used or made in connection with orders made by MAYO, a MAYO Affiliate or any physician, healthcare provider or other party associated with MAYO or a MAYO Affiliate.  Notwithstanding the foregoing, however, transfers by EXACT of Licensed Products to Mayo Collaborative Services, LLC shall be considered transfers for purposes of determining Net Sales and for calculating Earned Royalties 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 11 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		in those instances in which such Licensed Product is used as a test for a patient and ordered by a third party other than MAYO, a MAYO Affiliate or any physician or other party associated with MAYO or a MAYO Affiliate.  
		

		
			 
		

		
			The Earned Royalties shall be paid as follows:
		

		
			 
		

		
			(a)[***] percent ([***]%) of the Net Sales of Cologuard;
		

		
			(b)[***] percent ([***]%) of Net Sales of Licensed Products, other than Lung Cancer Collaboration Licensed Products, that are commercially launched after Cologuard; 
		

		
			(c)[***] percent ([***]%) of the Net Sales of any Lung Cancer Collaboration Licensed Product, if,  and only if, such Lung Cancer Collaboration Licensed Product (I) is (i) described by a pending claim of the Patent Rights; or (ii) would infringe an issued claim of the Patent Rights, or that would infringe but for the exception in 35 U.S.C. §271(e)(1), or similar exception in the United States or other countries; or (II) is developed, in material part, based on the research and development efforts of MAYO in collaboration with EXACT and a third party pursuant to Section 2.06 of this Restated Agreement, the Sponsored Research Agreement or a separate agreement between EXACT and MAYO; provided, however, that for purpose of this subsection, the definition of “Patent Rights” shall exclude 1.15(d); and
		

		
			(d)If Cologuard is subject to an Update, Improvement or Replacement that includes a new biological marker or material technical improvement that is developed or identified by MAYO alone or in collaboration EXACT, the royalty payments to MAYO on Net Sales of Cologuard will increase [***]% for each such marker or technical improvement, with a maximum total royalty payment of [***]% of Net Sales.  Such increased royalty shall be effective as of the commercial launch of such Licensed Product.
		

		
			 
		

		
			3.04MINIMUM ROYALTIES.  EXACT shall pay MAYO an annual minimum royalty (“Annual Minimum Royalty”) of TWENTY-FIVE THOUSAND DOLLARS (US $25,000) during the Term.  Beginning with calendar year 2015, if in any calendar year during the Term the aggregate amount of the Earned Royalty payments made during such year is less than the applicable Annual Minimum Royalty for such year (a “Shortfall”), then EXACT shall make an additional payment to MAYO in the amount of the Shortfall together with the fourth quarter Earned Royalty payment for such year. For the avoidance of doubt, TWELVE THOUSAND FIVE HUNDRED DOLLARS ($12,500) of the TWENTY-FIVE THOUSAND DOLLAR ($25,000) payment received on June 26 2014 shall be applied to calendar year 2015.
		

		
			 
		

		
			3.05COMPENSATION TO MAYO FOR AHLQUIST KNOW-HOW.  For the 2014 calendar year, EXACT will pay MAYO a total of [***] DOLLARS (US $[***]; $[***] per day) [***].  This amount will be payable following receipt by EXACT of an invoice from MAYO.  The financial information in this Section 3.05 is MAYO’s Confidential Information.  
		

		
			 
		

		
			This amount will be adjusted each calendar year based on that year’s rate of salary and benefits for Dr. Ahlquist.
		

		
			 
		

		
			3.06TAXES.  EXACT is responsible for all taxes, duties, import deposits, assessments, and other governmental charges, however designated, which are now or hereafter imposed by any 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 12 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		authority on EXACT: (a) by reason of the performance by MAYO of its obligations under this Restated Agreement, or the payment of any amounts by EXACT to MAYO under this Restated Agreement; (b) based on the Patent Rights; or (c) related to use, sale or import of the Licensed Product.  Any withholding taxes which EXACT is required by law to withhold on remittance of the royalty payments shall be deducted from the royalty paid and EXACT shall promptly furnish MAYO with original copies of all official receipts for such taxes.  EXACT will obtain, or assist MAYO in obtaining, any tax reduction (including avoidance of double taxation), tax refund or tax exemption available to MAYO by treaty or otherwise.  Notwithstanding the foregoing, MAYO shall be responsible for paying and withholding all employment related taxes with respect to the services of Dr. Ahlquist and his laboratory staff.
		

		
			 
		

		
			3.07U.S. CURRENCY.  All payments to MAYO under this Restated Agreement will be made by draft drawn on a U.S. bank, and payable in U.S. dollars.  In the event that conversion from foreign currency is required in calculating a payment under this Restated Agreement, the exchange rate used shall be the Interbank rate quoted by Citibank at the end of the last business day of the quarter in which the payment accrued.
		

		
			 
		

		
			3.08OVERDUE PAYMENTS.  If overdue, the payments due under this Restated Agreement shall bear interest until paid at a per annum rate two percent (2%) above the prime rate in effect at Citibank on the due date and MAYO shall be entitled to recover, in addition to all other remedies, reasonable attorneys’ fees and costs related to the administration or enforcement of this Restated Agreement, including collection of payments, following such failure to pay.  The acceptance of any payment, including of such interest shall not foreclose MAYO from exercising any other right or seeking any other remedy that it may have as a consequence of the failure of EXACT to make any payment when due.
		

		
			 
		

		
			Article 4.00 — Accounting and Reports
		

		
			 
		

		
			4.01REPORTS AND PAYMENT.  EXACT will deliver to MAYO on or before the following dates: 1 February, 1 May, 1 August, and 1 November, a written report setting forth a full accounting showing how any Earned Royalties due to MAYO for the preceding calendar quarter have been calculated as provided in this Restated Agreement, including an accounting of total Net Sales with a reporting of any applicable foreign exchange rates, deductions, allowances, and charges.  If no Licensed Product transfers have occurred and no other amounts are due to MAYO, EXACT will submit a report so stating.  Each such report will be accompanied by the payment of all amounts due for such calendar quarter. 
		

		
			 
		

		
			4.02ACCOUNTING.  EXACT will keep complete, continuous, true, and accurate books of accounts and records sufficient to support and verify diligence and the calculation of Net Sales, all royalties and any other amount believed due and payable to MAYO under this Restated Agreement.  Such books and records will be kept at EXACT’s principal place of business for at least three years after the end of the calendar year to which they pertain, and will be open at all reasonable times for inspection by a representative of MAYO for verification of royalty statements or compliance with other aspects of this Restated Agreement.  The MAYO representative will treat as confidential all relevant matters and will be a person or firm reasonably acceptable to EXACT.  In the event such audit reveals an underpayment by EXACT, 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 13 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		EXACT will within thirty (30) days pay the royalty due in excess of the royalty actually paid.  In the event the audit reveals an underpayment by EXACT of more than five percent (5%) of the amount due, EXACT will pay interest on the royalty due in excess of the royalty actually paid at a per annum rate two per cent (2%) above the prime rate in effect at Citibank on the date notice of the deficiency is provided to EXACT, and EXACT will pay all of MAYO’s costs in conducting the audit.
		

		
			 
		

		
			Article 5.00 — Diligence
		

		
			 
		

		
			5.01DEVELOPMENT PLAN.  EXACT will make commercially reasonable efforts to bring Licensed Products to market.
		

		
			 
		

		
			5.02DEVELOPMENT MILESTONES.  In partial satisfaction of its obligations to bring Licensed Products to market, EXACT will provide MAYO with development milestones within six (6) months of the Effective Date.  EXACT will promptly notify MAYO upon the achievement each of the development milestones, identify whether EXACT or a Sublicensee is responsible for the achievement of such milestone, and the actual date of such achievement.
		

		
			 
		

		
			5.03DILIGENCE REPORTS.  EXACT will provide MAYO with annual reports within thirty (30) days of each anniversary of the Effective Date describing in detail: (a) as of that reporting period, all development and marketing activities for each Licensed Product (other than Lung Cancer Collaboration Licensed Products) and the names of all Sublicensees, including which of the Sublicensees are Affiliates; and (b) an updated development plan for the next annual period.  
		

		
			 
		

		
			5.04THIRD PARTY COLLABORATIONS REGARDING ANCILLARY PRODUCTS.  To the extent EXACT does not have currently-available resources to develop and bring to market a commercially-viable new product identified by the Parties pursuant to their work under this Restated Agreement, which is covered by a jointly owned Patent Right, and which is not competitive with any existing or planned EXACT product (an “Ancillary Product”), the Parties agree to use their good faith, commercially reasonable efforts to explore entering into an agreement with a third party pursuant to which such third party would undertake such development and/or marketing activities and would provide the Parties with royalties, milestone payments, and/or such other consideration upon which the Parties may agree between themselves and with such third party.  The Parties will schedule a meeting or phone conference to discuss this topic at least once per year.        
		

		
			 
		

		
			Article 6.00 — Intellectual Property Management
		

		
			 
		

		
			6.01CONTROL.
		

		
			 
		

		
			(a)EXACT shall diligently prosecute and maintain the United States and foreign patents and patent applications covering Patent Rights as it deems appropriate, at EXACT’s expense, using counsel of its choice and after due consultation with MAYO.  EXACT shall provide MAYO with copies of all relevant documentation so that MAYO may be informed and apprised of the continuing prosecution and MAYO agrees to keep this documentation 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 14 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		confidential.  EXACT shall also notify MAYO of its intention to not apply for patent protection for any invention with a MAYO inventor or to abandon the prosecution of any patent within the Patent Rights thirty (30) days prior to any applicable deadlines affecting such application or abandonment.  Following such written notification and discussion between the Parties, MAYO shall be entitled to take over prosecution of such patent, at its own expense, of those patents within the Patent Rights that EXACT has elected not to pursue and, for MAYO owned patents and patent applications, EXACT shall then have no further rights to any patent that issues under such prosecution.  For jointly owned patents and patent applications, EXACT shall retain its ownership rights.  
		

		
			 
		

		
			(b)The Parties shall take commercially reasonable steps to ensure that the Know-How & Materials remain confidential in accordance with Article 8.
		

		
			 
		

		
			6.02PATENT TERM EXTENSION.  EXACT shall consult with MAYO in selecting the patent within the Patent Rights covering each Licensed Product for term extension for or supplementary protection certificate under in accordance with the applicable laws of any country.  Each Party agrees to execute any documents and to take any additional actions as the other Party may reasonably request in connection therewith.
		

		
			 
		

		
			6.03PATENT MARKING.  To the extent commercially feasible, EXACT will mark all Licensed Products that are manufactured or sold under this Restated Agreement with the number of each issued patent within the Patent Rights that covers such Licensed Product(s).  Any such marking will be in conformance with the patent laws and other laws of the country of manufacture or sale.
		

		
			 
		

		
			6.04ENFORCEMENT.  EXACT shall promptly inform MAYO in writing of any alleged or threatened infringement of any of the Patent Rights and/or Know-How & Materials and provide MAYO with any available evidence of such infringement.
		

		
			 
		

		
			(a)First Right.  EXACT shall have the first right, but not the obligation, to enforce the Patent Rights so long as MAYO is kept fully informed and given the right and opportunity to advise and comment.  MAYO shall reasonably cooperate in any such action at EXACT’s expense but shall not be required to join such action unless: (i) it has agreed to do so in writing prior to commencement thereof, or (ii) EXACT determines that MAYO is a necessary party in the action.  EXACT shall pay to MAYO twenty-five percent (25%) of any recovery or damages, net of all reasonable costs and expenses associated with each suit or settlement.
		

		
			 
		

		
			(b)Non-Election to Enforce.  If EXACT elects not to enforce the Patent Rights, it shall so notify MAYO in writing within ninety (90) days of receiving notice that an infringement may exist, and MAYO may, in its sole judgment and without any obligation, enforce, settle, and defend the Patent Rights and keep for its own account any recovery and damages.  EXACT shall reasonably cooperate in any such actions if requested to do so by MAYO, at MAYO’s expense.
		

		
			 
		

		
			6.05DEFENSE.  EXACT will have the first right, but not the obligation, to take any measures deemed appropriate by EXACT in consultation with MAYO, regarding challenges to the Patent Rights, Know-How or Materials brought (including interferences in the U.S. Patent 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 15 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		and Trademark Office and oppositions in foreign jurisdictions) and defense of the Patent Rights, Know-How or Materials required (including declaratory judgment actions).  MAYO shall reasonably cooperate in any such measures if requested to do so by EXACT at EXACT’s expense, but shall not be required to join any action unless: (i) it has agreed to do so in writing prior to commencement thereof, or (ii) the court determines that MAYO is a necessary party in the action.  EXACT shall be entitled to retain any related recovery, provided that all costs of MAYO related to such action have been fully paid by EXACT.  If EXACT elects not to defend the Patent Rights, it shall so notify MAYO in writing within ninety (90) days of receiving notice that a challenge has been made, and MAYO may, in its sole judgment and without any obligation, enforce, settle, and defend the Patent Rights and keep for its own account any related recovery.  EXACT shall reasonably cooperate in any such actions if requested to do so by MAYO, at MAYO’s expense.
		

		
			 
		

		
			6.06THIRD PARTY LITIGATION.  In the event a third party institutes a suit against EXACT for patent infringement involving a Licensed Product, EXACT will so inform MAYO within fifteen (15) business days and keep MAYO regularly informed of the proceedings.
		

		
			 
		

		
			Article 7.00 — Use of Name
		

		
			 
		

		
			7.01USE OF NAME AND LOGO.  Neither Party will use for publicity, promotion, or otherwise, any logo, name, trade name, service mark, or trademark of the other party or its Affiliates (in the case of MAYO, including, but not limited to, the terms “MAYO®,” “MAYO Clinic®,” and the triple shield MAYO logo, or any simulation, abbreviation, or adaptation of the same and in the case of EXACT, including, but not limited to, the terms “Exact Sciences” and “Cologuard”), or the name of any of the other Party’s employees or agents, without the other Party’s prior, written, express consent.  Each Party may withhold such consent in its absolute discretion.  With regard to the use of MAYO’s name, all requests for approval pursuant to this Section must be submitted to the Mayo Clinic Public Affairs Business Relations Group, at the following e-mail address: BusinessRelations@MAYO.edu at least five (5) business days prior to the date on which a response is needed. Notwithstanding the foregoing, Dr. Ahlquist and his MAYO colleagues may use EXACT’s corporate name and any trademarked name relating to a product developed under this Agreement in any non-commercial academic publications, educational settings, professional engagements, or in a conflict-of-interest disclosure
		

		
			 
		

		
			Article 8.00 — Confidentiality
		

		
			 
		

		
			8.01TREATMENT OF CONFIDENTIAL INFORMATION.  Except as provided for in Section 8.02, neither Party will disclose, use or otherwise make available the other’s Confidential Information during Term or for three years thereafter and will use the same degree of care it employs to protect its own confidential information.
		

		
			 
		

		
			8.02RIGHT TO DISCLOSE.
		

		
			 
		

		
			(a)To the extent it is reasonably necessary or appropriate to fulfill its obligations or exercise its rights under this Restated Agreement; a Party may use or disclose Confidential Information to its Sublicensees, consultants, and outside contractors on the condition that each 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 16 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		such entity agrees to obligations of confidentiality and non-use at least as stringent as those therein.
		

		
			 
		

		
			(b)If a Party is required by law, regulation or court order to disclose any of the Confidential Information, it will have the right to do so, provided it: (i) promptly notifies the disclosing party; and (ii) reasonably assists the disclosing party to obtain a protective order or other remedy of disclosing party’s election and at disclosing party’s expense.
		

		
			 
		

		
			8.03CONFIDENTIALITY OF AGREEMENTS.  Except as otherwise required by law, the specific terms and conditions of this Restated Agreement shall be Confidential Information but the existence and Field of this Restated Agreement will not be Confidential Information and the Parties may state that EXACT is licensed under the Patent Rights.  Notwithstanding the foregoing, a Party may disclose the contents of this Restated Agreement to its actual or prospective investors, professional advisors, and as required by law or the rules of any applicable securities exchange.
		

		
			 
		

		
			8.04PUBLICATION.  To enable the receiving Party to secure adequate intellectual property protection that would be affected by a public disclosure, MAYO and EXACT will submit any manuscript or material for any proposed academic publication, meeting, conference, or talk (“Public Disclosure”) of research underlying Patent Rights to the other Party at least 30 days before transmission of any manuscript or material to a third party (or at least 30 days before Public Disclosure where no manuscript or material exists), and the receiving Party shall have the right to review and comment upon the Public Disclosure in order to protect confidential information. Upon the receiving Party’s request, publication will be delayed up to 60 additional days.  Notwithstanding the above, the Public Disclosure shall not include EXACT Confidential Information without prior approval by EXACT.  
		

		
			 
		

		
			Article 9.00 — Warranties, Representations, Disclaimers and Indemnification
		

		
			 
		

		
			9.01REPRESENTATIONS AND WARRANTIES OF EXACT.  EXACT warrants and represents to MAYO that:
		

		
			 
		

		
			(a)it is experienced in the development, production, quality control, service, manufacture, marketing, and sales of products similar to the subject matter of the Patent Rights, and that it will commit itself to a thorough, vigorous, and diligent program of developing and marketing Licensed Products;
		

		
			 
		

		
			(b)it has independently evaluated the Patent Rights, Know-How, Materials and Confidential Information, if any, their applicability or utility in EXACT’s activities, is entering into this Restated Agreement on the basis of its own evaluation and not in reliance of any representation by MAYO, and assumes all risk and liability in connection with such determination;
		

		
			 
		

		
			(c)the execution and delivery of this Restated Agreement has been duly authorized and no further approval, corporate or otherwise, is required in order to execute this binding Restated Agreement;
		

		

		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 17 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		(d)it shall comply and require its Sublicensees to comply with all applicable international, national, and state laws, ordinances and regulations in its performance under this Restated Agreement; and
		

		
			 
		

		
			(e)its rights and obligations under this Restated Agreement do not conflict with any contractual obligation or court or administrative order by which it is bound.
		

		
			 
		

		
			9.02REPRESENTATIONS AND WARRANTIES OF MAYO.  MAYO warrants and represents to EXACT that:
		

		
			 
		

		
			(a)it is the owner of the Patent Rights and has full power and authority to grant the licenses which are provided for in this Restated Agreement;
		

		
			 
		

		
			(b)the execution and delivery of this Restated Agreement has been duly authorized and no further approval, corporate or otherwise, is required in order to execute this binding Restated Agreement;
		

		
			 
		

		
			(c)to the best of its internal counsel’s knowledge, its rights and obligations under this Restated Agreement do not conflict with any contractual obligation or court or administrative order by which it is bound;
		

		
			 
		

		
			(d)no claim, suit or action has been made or initiated alleging that the Patent Rights are invalid or that the practice of the Patent Rights will infringe the rights of any third party; and
		

		
			 
		

		
			(e)to the best of its internal counsel’s knowledge the Patent Rights are valid and subsisting.
		

		
			 
		

		
			9.03DISCLAIMERS.
		

		
			 
		

		
			(a)EXCEPT AS EXPRESSLY SET FORTH HEREIN, NEITHER PARTY HAS MADE ANY PROMISES, COVENANTS, GUARANTEES, REPRESENTATIONS OR WARRANTIES OF ANY NATURE, DIRECTLY OR INDIRECTLY, EXPRESS, STATUTORY OR IMPLIED, INCLUDING WITHOUT LIMITATION, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, SUITABILITY, DURABILITY, CONDITION, QUALITY, OR ANY OTHER CHARACTERISTIC OF THE LICENSED PRODUCT, KNOW-HOW, MATERIALS OR PATENT RIGHTS.
		

		
			 
		

		
			(b)KNOW-HOW, MATERIALS, CONFIDENTIAL INFORMATION AND PATENT RIGHTS ARE PROVIDED “AS IS,” “WITH ALL FAULTS,” AND “WITH ALL DEFECTS,” AND EXACT EXPRESSLY WAIVES ALL RIGHTS TO MAKE ANY CLAIM WHATSOEVER AGAINST MAYO FOR MISREPRESENTATION OR FOR BREACH OF PROMISE, GUARANTEE, REPRESENTATION OR WARRANTY OF ANY KIND RELATING TO THE LICENSED PRODUCTS, KNOW-HOW, MATERIALS, CONFIDENTIAL INFORMATION OR PATENT RIGHTS, EXCEPT AS EXPRESSLY SET FORTH HEREIN.  MAYO EXPRESSLY DISCLAIMS ANY IMPLIED WARRANTIES 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 18 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		ARISING FROM ANY COURSE OF DEALING, USAGE, OR TRADE PRACTICE, WITH RESPECT TO: THE SCOPE, VALIDITY OR ENFORCEABILITY OF THE PATENT RIGHTS, KNOW-HOW, OR MATERIALS; THAT ANY PATENT WILL ISSUE BASED UPON ANY PENDING PATENT APPLICATION; OR THAT THE MANUFACTURE, USE, SALE, OFFER FOR SALE OR IMPORTATION OF THE LICENSED PRODUCTS WILL NOT INFRINGE OTHER INTELLECTUAL PROPERTY RIGHTS.  NOTHING IN THIS RESTATED AGREEMENT WILL BE CONSTRUED AS AN OBLIGATION FOR MAYO TO BRING, PROSECUTE OR DEFEND ACTIONS REGARDING THE PATENT RIGHTS, KNOW-HOW OR MATERIALS.
		

		
			 
		

		
			(c)EXACT AGREES THAT MAYO AND ITS AFFILIATES WILL NOT BE LIABLE FOR ANY LOSS OR DAMAGE CAUSED BY OR ARISING OUT OF ANY RIGHTS GRANTED OR PERFORMANCE MADE UNDER THIS RESTATED AGREEMENT, WHETHER TO OR BY EXACT, A SUBLICENSEE OR A THIRD PARTY.  IN NO EVENT WILL MAYO’S LIABILITY OF ANY KIND INCLUDE ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE LOSSES OR DAMAGES, EVEN IF MAYO HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, OR EXCEED THE TOTAL AMOUNT OF ROYALTIES WHICH HAVE ACTUALLY BEEN PAID TO MAYO BY EXACT AS OF THE DATE OF FILING AN ACTION AGAINST MAYO WHICH RESULTS IN THE SETTLEMENT OR AWARD OF DAMAGES TO EXACT.
		

		
			 
		

		
			9.04INDEMNIFICATION AND INSURANCE.
		

		
			 
		

		
			(a)EXACT will defend, indemnify, and hold harmless MAYO, MAYO’s Affiliates and their respective trustees, officers, agents, independent contractors and employees (“MAYO Indemnitees”) from any and all claims, actions, demands, judgments, losses, costs, expenses, damages and liabilities (including attorneys’ fees, court costs and other expenses of litigation), regardless of the legal theory asserted, arising out of or connected with: (a) the practice or exercise of any rights granted hereunder by or on behalf of EXACT or any Sublicensee; (b) research, development, design, manufacture, distribution, use, sale, importation, exportation or other disposition of Licensed Products; and (c) any act or omission of EXACT or any Sublicensee hereunder, including the negligence or willful misconduct thereof.  MAYO and MAYO Affiliates shall have no obligation to indemnify EXACT hereunder.  Notwithstanding the foregoing, the indemnity obligations of EXACT shall not apply with respect to any claims, actions, demands, judgments, losses, costs, expenses, damages and liabilities which arise due to a breach of this Restated Agreement by MAYO or the gross negligence or willful misconduct of MAYO or its agents or employees.
		

		
			 
		

		
			(b)The Parties agree that this indemnity should be construed and applied in favor of maximum indemnification of MAYO Indemnitees.
		

		
			 
		

		
			(c)Commencing on the date of first commercial sale of a Licensed Product by EXACT, EXACT will continuously carry claim-based liability insurance, including products liability and contractual liability, in an amount and for a time period sufficient to cover the liability assumed by EXACT hereunder during the Term and after, such amount being at least 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 19 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		THREE MILLION DOLLARS (US $3,000,000).  In addition, such policy will name MAYO and its Affiliates as additional-named insureds.  In such case, EXACT will self-insure or obtain, at its cost, an extended reporting endorsement upon termination of this Restated Agreement sufficient to cover the liability assumed by EXACT hereunder for as long as the appropriate statute of limitations.  The minimum limits of any insurance coverage required herein shall not limit EXACT’s liability.
		

		
			 
		

		
			9.05PROHIBITION AGAINST INCONSISTENT STATEMENTS.  EXACT shall not make any statements, representations or warranties, or accept any liabilities or responsibilities whatsoever which are inconsistent with any disclaimer or limitation included in this section or any other provision of this Restated Agreement.  EXACT shall not settle any matter that will incur liability for MAYO or require MAYO to make any admission of liability without MAYO’s prior written consent.
		

		
			 
		

		
			Article 10.00 — Term and Termination
		

		
			 
		

		
			10.01TERM.  This Restated Agreement will expire at the end of the Term.
		

		
			 
		

		
			10.02TERMINATION FOR BREACH.  If EXACT commits a material breach of this Restated Agreement, including without limitation, the failure to make any required royalty or fee payments hereunder, MAYO will notify EXACT in writing of such breach and EXACT will have thirty (30) days after such notice to cure such breach to MAYO’s satisfaction.  If EXACT fails to cure such breach, MAYO may, at its sole option, terminate this Restated Agreement in whole or in part by sending EXACT written notice of termination.
		

		
			 
		

		
			10.03TERMINATION FOR SUIT.  MAYO does not license entities that bring suit against MAYO or its Affiliates and as such, MAYO may immediately terminate this Restated Agreement if EXACT or any Sublicensee directly or indirectly brings any action or proceeding against MAYO or its Affiliates, except for an uncured material breach of this Restated Agreement by MAYO.
		

		
			 
		

		
			10.04TERMINATION BY EXACT.  Subject to the terms of the Sponsored Research Restated Agreement, EXACT may without cause terminate this Restated Agreement at any time following payment and delivery of the compensation provided for in Section 3.01, upon written notice to MAYO.
		

		
			 
		

		
			10.05INSOLVENCY OF EXACT.  This Restated Agreement terminates immediately without an obligation of notice of termination to EXACT in the event EXACT ceases conducting business in the normal course, becomes insolvent or bankrupt, makes a general assignment for the benefit of creditors, admits in writing its inability to pay its debts as they are due, permits the appointment of a receiver for its business or assets, or avails itself of or becomes subject to any proceeding under any statute of any governing authority relating to insolvency or the protection of rights of creditors.
		

		
			 
		

		
			10.06SURVIVAL.  The termination or expiration of this Restated Agreement does not relieve either Party of its rights and obligations that have previously accrued.  After the Term, all rights 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 20 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		granted immediately revert to MAYO.  All Confidential Information of the other Party shall be returned or destruction certified, at the disclosing party’s election.  Rights and obligations that by their nature prescribe continuing rights and obligations shall survive the termination or expiration of this Restated Agreement including Sections 4.02, 9.04, 10.05 and Articles 7, 8 and 11.  EXACT and its Sublicensees shall provide an accounting for and pay, within thirty (30) days of termination or expiration, all amounts due hereunder.  Upon any termination of this Restated Agreement, the licenses granted hereunder shall cease.  Upon expiration of this Restated Agreement, the licenses granted hereunder shall become fully paid up.
		

		
			 
		

		
			Article 11.00 — General Provisions
		

		
			 
		

		
			11.01ASSIGNMENT AND TRANSFER.  Each Party is strictly prohibited from assigning, delegating or otherwise transferring any of its obligations or rights under this Restated Agreement without the other Party’s prior, express and written consent, which shall not be unreasonably withheld.  Any assignment, delegation or transfer in contravention hereof is null and void.  Notwithstanding the foregoing, EXACT may assign this Restated Agreement to an Affiliate and either Party may assign this Restated Agreement, in whole or in part, without approval in connection with a sale, merger or other transaction which involves the transfer of substantially all of the assets of a Party used in connection with any business of such Party that relates to this Restated Agreement.  Any assignment shall not in any manner relieve the assignor from liability for the performance of this Restated Agreement by its assignee and shall not otherwise affect the terms or conditions under this Restated Agreement.  The assignor shall provide prompt notice to the other Party upon making such assignment.
		

		
			 
		

		
			11.02WAIVER.  No part of this Restated Agreement may be waived except by the further written agreement of the Party granting such waiver.  Forbearance in any form from demanding the performance of a duty owed under this Restated Agreement is not a waiver of that duty.  Until complete performance of a duty owed under this Restated Agreement is accomplished, the Party to which that duty is owed may invoke any remedy under this Restated Agreement or under law, despite its past forbearance in demanding performance of that duty.
		

		
			 
		

		
			11.03GOVERNING LAW AND JURISDICTION.  This Restated Agreement is made and performed in Minnesota.  The terms and conditions of this Restated Agreement, as well as all disputes arising under or relating to this Restated Agreement, shall be governed by Minnesota law, specifically excluding its choice-of-law principles, except that the interpretation, validity and enforceability of the Patent Rights will be governed by the patent laws of the country in which the patent application is pending or issued.  This is not an agreement for the sale of goods and as such Article 2 of the Uniform Commercial Code as enacted in Minnesota does not apply.
		

		
			 
		

		
			11.04HEADINGS.  The headings of articles and sections used in this document are for convenience of reference only.
		

		
			 
		

		
			11.05NOTICES.  Any notice required to be given under this Restated Agreement is properly provided if in writing and sent to the Party at its address or facsimile number below, or as otherwise designated by the Party in accordance with this provision, and duly given or made: (a) on the date delivered in person; (b) on the date transmitted by facsimile, if confirmation is 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 21 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		received; (c) three (3) days after deposit in the mail if sent by certified U.S. mail postage prepaid, return receipt requested; and (d) one (l) day after deposit with a nationally recognized overnight carrier service with charges prepaid.
		

		
			 
		

		
			For MAYO:
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						Mayo Foundation for Medical Education and Research

				
	
					
						Mayo Clinic Ventures -BB4

				
	
					
						200 First Street SW

				
	
					
						Rochester, Minnesota 55905-0001

				
	
					
						Attn:

					
					
						 

					
					
						Ventures Operations

				
	
					
						Phone:

					
					
						 

					
					
						(507) 293-3900

				
	
					
						Facsimile:

					
					
						 

					
					
						(507) 284-5410

				
	
					
						Email:

					
					
						 

					
					
						intellectualproperty@mayo.edu

				
	
					
						Fed Tax ID:

					
					
						 

					
					
						41-1506440

				

		
			 
		

		
			For EXACT:
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						Exact Sciences Corporation

				
	
					
						441 Charmany Drive,

				
	
					
						Madison, WI 53719

				
	
					
						Attn:

					
					
						 

					
					
						Maneesh Arora

				
	
					
						Phone:

					
					
						 

					
					
						(508) 683-1200

				
	
					
						Fax:

					
					
						 

					
					
						(508) 683-1201

				
	
					
						Email:

					
					
						 

					
					
						marora@exactsciences.com

				

		
			 
		

		
			11.06LIMITATION OF RIGHTS CREATED.  This Restated Agreement is personal to the Parties and shall be binding on and inure to the sole benefit of the Parties and their permitted successors and assigns and shall not be construed as conferring any rights to any third party.  Specifically, no interests are intended to be created for any customer, patient, research subjects, or other persons (or their relatives, heirs, dependents, or personal representatives) by or upon whom the Licensed Products may be used.
		

		
			 
		

		
			11.07INDEPENDENT CONTRACTORS.  EXACT and any Sublicensee is an independent contractor not an agent, employee, partner, joint venturer or servant of MAYO and has no right to obligate or bind MAYO in any manner.
		

		
			 
		

		
			11.08ENTIRE AGREEMENT.  This Restated Agreement states the entire agreement and understanding between the Parties about its subject matter.  All past and contemporaneous discussions, writings, agreements, proposals, promises, covenants, warranties, representations, guarantees, correspondence, and understandings, whether oral or written, formal or informal, are entirely superseded by this Restated Agreement, with the exception of (a) the material transfer agreement for 200 stool and tissue samples, effective 9 November 2000 and attached hereto as Exhibit E (MAYO agreement # 1683); and (b) the material transfer agreement for 80 blood samples, effective 9 November 2000 and attached hereto as Exhibit F (MAYO agreement # 1684).  For the avoidance of doubt, (a) the letter to Don Hardison regarding prosecution of joint 
		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 22 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		intellectual property, dated 3 January 2003 and attached hereto as Exhibit G (MAYO agreement # 1685); and (b) the confidentiality agreement effective 16 February 2009 and attached hereto as Exhibit H (MAYO agreement # 6049) are entirely superseded by this Restated Agreement.
		

		
			 
		

		
			11.09SEVERABILITY.  If any terms or conditions of this Restated Agreement are or become in conflict with the laws, regulations or court order of any jurisdiction or any governmental entity having jurisdiction over the Parties or this Restated Agreement, those terms and conditions shall be deemed automatically deleted in such jurisdiction(s) only, and the remaining terms and conditions of this Restated Agreement shall remain in full force and effect.  If such a deletion is not so allowed in a given jurisdiction or if such a deletion leaves terms and conditions thereby made clearly illogical or inappropriate in effect, the Parties agree to substitute new terms and conditions as similar in effect to the present terms of this Restated Agreement as may be allowed under the applicable laws, regulations or court order of such jurisdiction.  The Parties desire the terms and conditions herein to be valid and enforced to the maximum extent not prohibited by law, regulation or court order in a given jurisdiction.
		

		
			 
		

		
			11.10CHANGES TO AGREEMENT.  No terms or conditions of this Restated Agreement may be changed except in writing, through another document signed by both Parties, and expressly referencing this Restated Agreement.
		

		
			 
		

		
			11.11CONSTRUCTION.  Each Party acknowledges that it was provided an opportunity to seek advice of counsel and as such this Restated Agreement shall not be construed for or against either Party.
		

		
			 
		

		
			11.12REGISTRATION OF LICENSES.  EXACT will register and give required notice concerning this Restated Agreement, at its expense, in each country in the Territory where an obligation under law exists to so register or give notice.
		

		
			 
		

		
			11.13EXPORT CONTROL.  MAYO is subject to U.S. laws and regulations controlling the export of technical data, computer software, laboratory prototypes, and other commodities that may require a license from the applicable agency of the United States government and/or may require written assurances by EXACT that it will not export data or commodities to certain foreign countries without prior approval of such agency.  MAYO neither represents that a license is required, nor that, if required, it will be issued.
		

		
			 
		

		

		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 23 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		The Parties execute this Restated Agreement in one or more counterparts, each of which shall be deemed an original but all of which taken together constitute one and the same instrument, as of the Effective Date.
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Mayo Foundation for Medical 

					
						Education and Research

					
					
						 

					
					
						Exact Sciences Corporation:

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						/s/ Daniel D. Estes

					
					
						 

					
					
						/s/ Kevin Conroy

				
	
					
						Daniel D. Estes

					
					
						 

					
					
						Name: Kevin Conroy

				
	
					
						Assistant Treasurer

					
					
						 

					
					
						Title: Chief Executive Officer

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						Date

					
					
						January 30, 2015

					
					
						 

					
					
						Date

					
					
						February 2, 2015

				

		
			 
		

		
			 
		

		

		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 24 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		Exhibit  A
		

		
			Licensed Patents
		

		
			 
		

		
			Mayo Owned IP
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						App or Patent #

					
					
						Domain

					
					
						Patent Title

					
					
						Filing or Issue Date

					
					
						MAYO file #

				
	
					
						7,785,772

					
					
						USA

					
					
						Detecting Methylated Mammalian Nucleic Acid

					
					
						8/31/2010

					
					
						2006-274

				
	
					
						12/851,872

					
					
						USA

					
					
						in Stool

					
					
						8/6/2010

					
					
						 

				
	
					
						60/886,278

					
					
						USA

					
					
						 

					
					
						1/23/2007

					
					
						 

				
	
					
						8,673,555

					
					
						USA

					
					
						Detecting Neoplasm

					
					
						3/18/2014

					
					
						2007-312

				
	
					
						PCT/US2009/033793

					
					
						USA

					
					
						 

					
					
						2/11/2009

					
					
						2007-312

				
	
					
						09711056.3

					
					
						EPO

					
					
						 

					
					
						2/11/2009

					
					
						2007-312

				
	
					
						11189541.3

					
					
						EPO

					
					
						 

					
					
						2/11/2009

					
					
						2007-312

				
	
					
						61/029,221

					
					
						USA

					
					
						 

					
					
						2/15/2008

					
					
						2007-208

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						2007-209

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						2007-210

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						2007-211

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						2007-212

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						2007-213

				
	
					
						8,722,330

					
					
						USA

					
					
						Collecting and Processing Complex

					
					
						5/13/2014

					
					
						 

				
	
					
						12/555,672

					
					
						USA

					
					
						Macromolecular Mixtures

					
					
						9/8/2009

					
					
						 

				
	
					
						PCT/US2009/056252

					
					
						USA

					
					
						 

					
					
						9/8/2009

					
					
						 

				
	
					
						61/094,770

					
					
						USA

					
					
						 

					
					
						9/5/2008

					
					
						2007-211

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						2008-147

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						2008-199

				
	
					
						13/072,047

					
					
						USA

					
					
						Methods and Materials for Detecting Colorectal

					
					
						3/25/2011

					
					
						2009-133

				
	
					
						PCT/US2011/029959

					
					
						USA

					
					
						Neoplasm

					
					
						3/25/2011

					
					
						2009-133

				
	
					
						2011230633

					
					
						Australia

					
					
						 

					
					
						3/25/2011

					
					
						 

				
	
					
						2790416

					
					
						Canada

					
					
						 

					
					
						3/25/2011

					
					
						 

				
	
					
						11760295.3

					
					
						EPO

					
					
						 

					
					
						3/25/2011

					
					
						 

				
	
					
						61/318,077

					
					
						USA

					
					
						 

					
					
						3/26/2010

					
					
						2009-133

				
	
					
						61/452,350

					
					
						USA

					
					
						Methods and Materials for Using the Contents

					
					
						3/14/2011

					
					
						2010-325

				
	
					
						14/004,952

					
					
						USA

					
					
						of Phagocytes to Detect Neoplasms

					
					
						3/14/2012

					
					
						 

				
	
					
						PCT/US2012/029073

					
					
						USA

					
					
						 

					
					
						3/14/2012

					
					
						 

				
	
					
						60/989,578

					
					
						USA

					
					
						Removing Polypeptide from Stool

					
					
						11/21/2007

					
					
						2007-207

				
	
					
						8,735,168

					
					
						USA

					
					
						 

					
					
						5/27/14

					
					
						 

				
	
					
						PCT/US2008/084278

					
					
						 

					
					
						 

					
					
						11/21/2008

					
					
						 

				
	
					
						61/611,310

					
					
						USA

					
					
						Methods and Materials for Noninvasive Detection

					
					
						3/15/2012

					
					
						2010-046

				
	
					
						13/773,791

					
					
						USA

					
					
						of Colorectal Neoplasia Associated with

					
					
						2/21/2013

					
					
						 

				
	
					
						PCT/US13/27227

					
					
						USA

					
					
						Inflammatory Bowel Disease

					
					
						2/21/2013

					
					
						 

				
	
					
						61/784,429

					
					
						USA

					
					
						Detecting Neoplasm

					
					
						3/14/2013

					
					
						2012-250

				
	
					
						14/206,596

					
					
						USA

					
					
						 

					
					
						3/12/2014

					
					
						 

				
	
					
						PCT/US14/024582

					
					
						USA

					
					
						 

					
					
						3/12/2014

					
					
						 

				
	
					
						PCT/US14/024589

					
					
						USA

					
					
						 

					
					
						3/12/2014

					
					
						 

				
	
					
						61/452,350

					
					
						USA

					
					
						Materials and Methods for Using the Contents of

					
					
						3/14/2011

					
					
						2010-325

				
	
					
						PCT/US2012/029073

					
					
						USA

					
					
						Phagocytes to Detect Neoplasms

					
					
						 

					
					
						 

				
	
					
						14/004,952

					
					
						USA

					
					
						 

					
					
						 

					
					
						 

				
	
					
						62/055,737

					
					
						USA

					
					
						Detecting Cholangiocarcinoma

					
					
						9/26/2014

					
					
						2014-350

				

		
			 
		

		
			 
		

		

		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 25 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		Jointly (Mayo & Exact) Owned IP
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						App or Patent #

					
					
						Domain

					
					
						Patent Title

					
					
						Filing or Issue Date

					
					
						MAYO file #

				
	
					
						47142/01

					
					
						Australia

					
					
						Supracolonic Aerodigestive Neoplasm Detection

					
					
						12/7/2000

					
					
						2000-026

				
	
					
						2394921

					
					
						Canada

					
					
						 

					
					
						12/7/2000

					
					
						 

				
	
					
						00992876.3

					
					
						EPO

					
					
						 

					
					
						12/7/2000

					
					
						 

				
	
					
						2001-544020

					
					
						Japan

					
					
						 

					
					
						12/7/2000

					
					
						 

				
	
					
						PCT/US00/42683

					
					
						USA

					
					
						 

					
					
						12/7/2000

					
					
						 

				
	
					
						7,981,612

					
					
						USA

					
					
						Methods of Screening for Supracolonic 

					
					
						7/19/2011

					
					
						2000-026

				
	
					
						7,368,233

					
					
						USA

					
					
						Neoplasms Based on Stool Samples Containing a

					
					
						5/6/2008

					
					
						 

				
	
					
						60/196,074

					
					
						USA

					
					
						Nucleic Acid Marker Indicative of a Neoplasm

					
					
						4/10/2000

					
					
						 

				
	
					
						60/169,457

					
					
						USA

					
					
						 

					
					
						12/07/1999

					
					
						 

				
	
					
						13/364,978

					
					
						USA

					
					
						Digital Sequence Analysis of DNA Methylation

					
					
						2/2/2012

					
					
						2011-036

				
	
					
						PCT/US12/23646

					
					
						USA

					
					
						 

					
					
						2/2/2012

					
					
						 

				
	
					
						61/438,649

					
					
						USA

					
					
						 

					
					
						2/2/2011

					
					
						 

				
	
					
						13/575,831

					
					
						USA

					
					
						Methods and Materials for Detecting Colorectal 

					
					
						9/4/2012

					
					
						 

				
	
					
						PCT/US2011/029982

					
					
						USA

					
					
						Cancer and Adenoma

					
					
						3/25/2011

					
					
						2009-134

				
	
					
						61/318,670

					
					
						USA

					
					
						 

					
					
						3/29/2010

					
					
						2009-134

				
	
					
						PCT/US13/33047

					
					
						USA

					
					
						Marker Panel for Detecting Cancer

					
					
						3/20/2013

					
					
						2012-085

				
	
					
						61/613,252

					
					
						USA

					
					
						 

					
					
						3/20/2012

					
					
						 

				
	
					
						14/386,554

					
					
						USA

					
					
						 

					
					
						9/19/14

					
					
						 

				
	
					
						PCT/US14/24589

					
					
						USA

					
					
						Detecting Neoplasm

					
					
						3/12/2014

					
					
						 

				
	
					
						61/972,942

					
					
						USA

					
					
						Detecting Colorectal Neoplasm

					
					
						3/31/2014

					
					
						2013-178

				
	
					
						61/977,954

					
					
						USA

					
					
						 

					
					
						4/10/2014

					
					
						 

				
	
					
						62/091,053

					
					
						USA

					
					
						Compositions and Methods for Performing Methylation Detection Assays

					
					
						12/12/2014

					
					
						 

				

		
			 
		

		
			 
		

		

		

		 

		

			 

		

 

			

					

						Amended and Restated Agreement

					

					

						 

					

					

						page 26 of 26

				
	

					

						Mayo / Exact

					

					

						Execution Copy

					

					

						 

				

		

			 

		

		Exhibit B
		

		
			 
		

		
			Markers
		

		
			Markers identified by MAYO and subject to the agreement are found in the following disclosures and related patent applications:
		

		
			 
		

			
					
						 

					
					
						 

				
	
					
						Mayo File #

					
					
						Related Patent Applications

				
	
					
						2012-250

					
					
						61/784,429;  14/206,596;  PCT/US14/024582;  PCT/US14/024589

				
	
					
						2013-178

					
					
						61/972,942;  61/977,954

				
	
					
						2013-179

					
					
						 

				
	
					
						2014-068

					
					
						 

				
	
					
						2014-069

					
					
						 

				
	
					
						2014-350

					
					
						62/055,737

				
	
					
						2014-372

					
					
						 

				
	
					
						2015-040

					
					
						 

				
	
					
						2015-042

					
					
						 

				
	
					
						2015-043

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]